Spots Global Cancer Trial Database for refractory plasma cell myeloma
Every month we try and update this database with for refractory plasma cell myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT01946152 | Multiple Myelom... Recurrent Plasm... Refractory Plas... | Dexamethasone Filgrastim-sndz Laboratory Biom... Pomalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT03333746 | Recurrent Plasm... Refractory Plas... | Laboratory Biom... Lenalidomide Nivolumab Pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide | NCT01794039 | Recurrent Plasm... Refractory Plas... | Dexamethasone Lenalidomide Pomalidomide | 18 Years - | Mayo Clinic | |
| Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma | NCT05288062 | Plasma Cell Mye... Recurrent Plasm... Refractory Plas... Smoldering Plas... | Bone Marrow Bio... Dexamethasone Lenalidomide Pomalidomide | 18 Years - | Mayo Clinic | |
| Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT01989598 | Recurrent Plasm... Refractory Plas... | Laboratory Biom... Pharmacological... Trametinib Uprosertib | 18 Years - | National Cancer Institute (NCI) | |
| Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | NCT00869206 | Breast Adenocar... DS Stage I Plas... DS Stage II Pla... Metastatic Mali... Pain Musculoskeletal... Urinary Complic... | zoledronic acid | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant | NCT03015792 | Recurrent Plasm... Refractory Plas... | Dexamethasone Ibrutinib Laboratory Biom... Lenalidomide Pharmacological... Quality-of-Life... | 18 Years - | Mayo Clinic | |
| Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) | NCT04439240 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Plas... | FGFR Inhibitor ... | 18 Years - | National Cancer Institute (NCI) | |
| CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma | NCT03710421 | Recurrent Plasm... Refractory Plas... | CS1-CAR T Thera... Cyclophosphamid... Fludarabine Leukapheresis | 18 Years - | City of Hope Medical Center | |
| Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma | NCT00966693 | Recurrent Plasm... Refractory Plas... | Dexamethasone Lenalidomide Thalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT01503242 | Plasma Cell Mye... Refractory Plas... | Allogeneic Hema... Cyclosporine Fludarabine Pho... Mycophenolate M... Peripheral Bloo... Total-Body Irra... Yttrium Y 90 An... | 18 Years - 65 Years | Fred Hutchinson Cancer Center | |
| Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial | NCT05514990 | Recurrent Plasm... Refractory Plas... | Bortezomib Dexamethasone Pelareorep Pembrolizumab | 18 Years - | University of Southern California | |
| Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement | NCT02765854 | Recurrent Plasm... Refractory Plas... | Dexamethasone Ixazomib Lenalidomide | 18 Years - | Emory University | |
| Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | NCT00869206 | Breast Adenocar... DS Stage I Plas... DS Stage II Pla... Metastatic Mali... Pain Musculoskeletal... Urinary Complic... | zoledronic acid | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies | NCT04205409 | Recurrent Chron... Recurrent Diffu... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Non-H... Recurrent Plasm... Refractory Chro... Refractory Diff... Refractory Foll... Refractory Marg... Refractory Non-... Refractory Plas... Recurrent Mantl... Refractory Mant... | Nivolumab | 18 Years - | University of Washington | |
| Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | NCT04508790 | Recurrent Plasm... Refractory Plas... | Dexamethasone Leflunomide Pomalidomide | 18 Years - | City of Hope Medical Center | |
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma | NCT04579523 | Plasma Cell Mye... Recurrent Plasm... Refractory Plas... | Allogeneic Hema... Astatine At 211... Cyclophosphamid... Fludarabine Pho... Total-Body Irra... | 18 Years - 70 Years | Fred Hutchinson Cancer Center | |
| Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT01936090 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Bortezomib Total-Body Irra... Melphalan Autologous Bone... Autologous Hema... Peripheral Bloo... Laboratory Biom... | 18 Years - | Mayo Clinic | |
| Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT03763162 | Recurrent Plasm... Refractory Plas... | Bortezomib Daratumumab Dexamethasone Ixazomib Quality-of-Life... | 18 Years - | M.D. Anderson Cancer Center | |
| Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma | NCT05411497 | Recurrent Plasm... Refractory Plas... | Autologous MUC1... Cyclophosphamid... | 18 Years - | Mayo Clinic | |
| Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT02509052 | Recurrent Plasm... Refractory Plas... | Laboratory Biom... Leflunomide Pharmacological... | 18 Years - | City of Hope Medical Center | |
| Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide | NCT01794039 | Recurrent Plasm... Refractory Plas... | Dexamethasone Lenalidomide Pomalidomide | 18 Years - | Mayo Clinic | |
| Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia | NCT01372540 | Plasma Cell Leu... Recurrent Plasm... Refractory Plas... | Carfilzomib Filanesib Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center | |
| Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | NCT02119468 | Refractory Plas... Recurrent Plasm... | ixazomib citrat... dexamethasone pomalidomide | 18 Years - | City of Hope Medical Center | |
| Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT01533194 | Light Chain Dep... Refractory Plas... | Diagnostic Labo... Wild-type Reovi... | 18 Years - | National Cancer Institute (NCI) | |
| Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma | NCT04640779 | Recurrent Histi... Recurrent Hodgk... Recurrent Non-H... Recurrent Plasm... Refractory Hist... Refractory Hodg... Refractory Non-... Refractory Plas... | Choline Salicyl... Selinexor | 18 Years - | Mayo Clinic | |
| VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma | NCT03017820 | B-Cell Non-Hodg... Histiocytic and... Myelodysplastic... Previously Trea... Recurrent Adult... Recurrent Anapl... Recurrent Angio... Recurrent Mycos... Recurrent Plasm... Recurrent Prima... Recurrent T-Cel... Refractory Acut... Refractory Anap... Refractory Angi... Refractory Myco... Refractory Peri... Refractory Plas... Refractory Prim... Refractory T-Ce... | Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Positron Emissi... Recombinant Ves... Single Photon E... Cemiplimab | 18 Years - | Mayo Clinic | |
| Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia | NCT01008462 | B-Cell Prolymph... Hypodiploidy Loss of Chromos... Plasma Cell Leu... Progression of ... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Chron... Recurrent Plasm... Recurrent Small... Refractory Chil... Refractory Chro... Refractory Non-... Refractory Plas... Refractory Smal... t(14;16) t(4;14) T-Cell Prolymph... Waldenstrom Mac... | Allogeneic Bone... Allogeneic Hema... Autologous Hema... Autologous-Allo... Carmustine Cyclophosphamid... Cytarabine Etoposide Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Peripheral Bloo... Tacrolimus Total-Body Irra... | - 75 Years | Fred Hutchinson Cancer Center | |
| Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma | NCT03267888 | ISS Stage I Pla... ISS Stage II Pl... ISS Stage III P... Recurrent Plasm... Refractory Plas... | Pembrolizumab Radiation Thera... | 18 Years - | Emory University | |
| Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms | NCT00082784 | Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Refractory Plas... Splenic Margina... Waldenstrom Mac... | Bortezomib Alvocidib Hydro... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma | NCT03829020 | Recurrent Plasm... Refractory Plas... | Bortezomib Metformin Hydro... Nelfinavir Mesy... | 18 Years - | Mayo Clinic | |
| Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) | NCT04439240 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Plas... | FGFR Inhibitor ... | 18 Years - | National Cancer Institute (NCI) | |
| Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT03701321 | Recurrent Plasm... Refractory Plas... | Bortezomib Daratumumab Dexamethasone Venetoclax | 18 Years - | National Cancer Institute (NCI) | |
| Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab | NCT04407442 | Recurrent Plasm... Refractory Plas... | Azacitidine Daratumumab Dexamethasone | 18 Years - | University of California, San Francisco | |
| Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma | NCT04756401 | Recurrent Plasm... Refractory Plas... | Carfilzomib Daratumumab Dexamethasone Quality-of-Life... Selinexor | 18 Years - | Academic and Community Cancer Research United | |
| Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant | NCT02353468 | Refractory Plas... | Bortezomib Lenalidomide Dexamethasone | 19 Years - | University of Colorado, Denver | |
| FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00066638 | DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Romidepsin Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma | NCT00793572 | Refractory Plas... | Autologous Hema... Bortezomib Cyclosporine Cyclosporine Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Syngeneic Bone ... Total-Body Irra... | 18 Years - | Fred Hutchinson Cancer Center | |
| Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT01842308 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Autologous Bone... Autologous Hema... Carfilzomib Laboratory Biom... Melphalan | 18 Years - | Mayo Clinic | |
| Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT02086552 | Recurrent Plasm... Refractory Plas... | Laboratory Biom... Lenalidomide Sonidegib | 18 Years - | Mayo Clinic | |
| Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT03333746 | Recurrent Plasm... Refractory Plas... | Laboratory Biom... Lenalidomide Nivolumab Pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma | NCT03502577 | Recurrent Plasm... Refractory Plas... | BCMA-specific C... Cyclophosphamid... Fludarabine Gamma-Secretase... Laboratory Biom... Pharmacokinetic... | 21 Years - | Fred Hutchinson Cancer Center | |
| Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma | NCT01163357 | Autologous Hema... Loss of Chromos... Plasma Cell Leu... Recurrent Plasm... Refractory Plas... | bortezomib fludarabine pho... melphalan total marrow ir... tacrolimus sirolimus peripheral bloo... laboratory biom... | 18 Years - 70 Years | City of Hope Medical Center | |
| Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT01989598 | Recurrent Plasm... Refractory Plas... | Laboratory Biom... Pharmacological... Trametinib Uprosertib | 18 Years - | National Cancer Institute (NCI) | |
| Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma | NCT04892264 | Plasma Cell Mye... Recurrent Plasm... Refractory Plas... | Belantamab Mafo... Daratumumab Dexamethasone Lenalidomide Quality-of-Life... Biospecimen Col... Skeletal Survey... Low Dose Comput... Bone Marrow Asp... Bone Marrow Bio... | 18 Years - | Mayo Clinic | |
| Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma | NCT03202628 | Recurrent Plasm... Refractory Plas... | Autologous Hema... Dexamethasone Ixazomib Citrat... Laboratory Biom... Pomalidomide | 18 Years - | Mayo Clinic | |
| Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib | NCT01415882 | Recurrent Plasm... Refractory Plas... | Cyclophosphamid... Daratumumab Dexamethasone Ixazomib Citrat... Laboratory Biom... | 18 Years - | Mayo Clinic | |
| VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma | NCT03017820 | B-Cell Non-Hodg... Histiocytic and... Myelodysplastic... Previously Trea... Recurrent Adult... Recurrent Anapl... Recurrent Angio... Recurrent Mycos... Recurrent Plasm... Recurrent Prima... Recurrent T-Cel... Refractory Acut... Refractory Anap... Refractory Angi... Refractory Myco... Refractory Peri... Refractory Plas... Refractory Prim... Refractory T-Ce... | Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Positron Emissi... Recombinant Ves... Single Photon E... Cemiplimab | 18 Years - | Mayo Clinic | |
| Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT02514382 | Recurrent Plasm... Refractory Plas... | Bortezomib Dexamethasone Laboratory Biom... Pharmacological... Wild-type Reovi... | 18 Years - | University of Southern California | |
| Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies | NCT05191472 | Multiple Myelom... Multiple Myelom... Multiple Myelom... Recurrent Plasm... Refractory Plas... | Pembrolizumab | 18 Years - | University of California, San Francisco | |
| Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma | NCT00793572 | Refractory Plas... | Autologous Hema... Bortezomib Cyclosporine Cyclosporine Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Syngeneic Bone ... Total-Body Irra... | 18 Years - | Fred Hutchinson Cancer Center | |
| TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma | NCT03506802 | HLA-A*0201 Posi... NY-ESO-1 Positi... Recurrent Plasm... Refractory Plas... | 18F-FHBG Aldesleukin Cellular Therap... Computed Tomogr... Filgrastim Laboratory Biom... Lenalidomide Leukapheresis Melphalan Plerixafor Positron Emissi... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma | NCT04850599 | Recurrent Plasm... Refractory Plas... | Carfilzomib Isatuximab Pomalidomide | 18 Years - | OHSU Knight Cancer Institute | |
| Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma | NCT00445692 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Clarithromycin Dexamethasone Lenalidomide | 18 Years - | Fred Hutchinson Cancer Center | |
| Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant | NCT03015792 | Recurrent Plasm... Refractory Plas... | Dexamethasone Ibrutinib Laboratory Biom... Lenalidomide Pharmacological... Quality-of-Life... | 18 Years - | Mayo Clinic | |
| Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma | NCT04756401 | Recurrent Plasm... Refractory Plas... | Carfilzomib Daratumumab Dexamethasone Quality-of-Life... Selinexor | 18 Years - | Academic and Community Cancer Research United | |
| Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma | NCT01301807 | Non-Secretory P... Plasmacytosis Recurrent Plasm... Refractory Plas... | Carfilzomib Panobinostat | 18 Years - | M.D. Anderson Cancer Center | |
| Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer | NCT00789776 | Acute Lymphobla... Acute Myeloid L... Aggressive Non-... Diffuse Large B... Previously Trea... Recurrent Chron... Recurrent Chron... Recurrent Indol... Recurrent Mantl... Recurrent Plasm... Recurrent Small... Refractory Chro... Refractory Hodg... Refractory Plas... Refractory Smal... Waldenstrom Mac... | Allogeneic Bone... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Mycophenolate M... Natural Killer ... Tacrolimus Total-Body Irra... | - | Fred Hutchinson Cancer Center | |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT01646762 | Refractory Plas... | Paclitaxel Albu... Laboratory Biom... | 18 Years - | Mayo Clinic | |
| Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab | NCT04407442 | Recurrent Plasm... Refractory Plas... | Azacitidine Daratumumab Dexamethasone | 18 Years - | University of California, San Francisco | |
| Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma | NCT00793572 | Refractory Plas... | Autologous Hema... Bortezomib Cyclosporine Cyclosporine Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Syngeneic Bone ... Total-Body Irra... | 18 Years - | Fred Hutchinson Cancer Center | |
| Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT01605032 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Busulfan Melphalan Bortezomib Autologous Hema... Peripheral Bloo... | 18 Years - 72 Years | Albert Einstein College of Medicine | |
| Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant | NCT02353468 | Refractory Plas... | Bortezomib Lenalidomide Dexamethasone | 19 Years - | University of Colorado, Denver | |
| Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma | NCT02506959 | Plasma Cell Leu... Plasmacytoma Recurrent Plasm... Refractory Plas... | Autologous Hema... Busulfan Gemcitabine Hyd... Laboratory Biom... Melphalan Panobinostat Peripheral Bloo... Pharmacological... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma | NCT01330173 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Vismodegib Pharmacological... Laboratory Biom... | 18 Years - | National Cancer Institute (NCI) | |
| Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies | NCT05191472 | Multiple Myelom... Multiple Myelom... Multiple Myelom... Recurrent Plasm... Refractory Plas... | Pembrolizumab | 18 Years - | University of California, San Francisco | |
| Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) | NCT04439214 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Plas... | Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma | NCT01163357 | Autologous Hema... Loss of Chromos... Plasma Cell Leu... Recurrent Plasm... Refractory Plas... | bortezomib fludarabine pho... melphalan total marrow ir... tacrolimus sirolimus peripheral bloo... laboratory biom... | 18 Years - 70 Years | City of Hope Medical Center | |
| Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT01936090 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Bortezomib Total-Body Irra... Melphalan Autologous Bone... Autologous Hema... Peripheral Bloo... Laboratory Biom... | 18 Years - | Mayo Clinic | |
| Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia | NCT01372540 | Plasma Cell Leu... Recurrent Plasm... Refractory Plas... | Carfilzomib Filanesib Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center | |
| Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma | NCT00445692 | DS Stage I Plas... DS Stage II Pla... DS Stage III Pl... Refractory Plas... | Clarithromycin Dexamethasone Lenalidomide | 18 Years - | Fred Hutchinson Cancer Center | |
| Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma | NCT03713294 | Refractory Plas... | Dexamethasone Elotuzumab Pomalidomide | 18 Years - | Mayo Clinic | |
| Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia | NCT02948283 | Anemia Fatigue Fever Lymphadenopathy Lymphocytosis Night Sweats Recurrent Chron... Recurrent Plasm... Refractory Chro... Refractory Plas... Splenomegaly Thrombocytopeni... Weight Loss | Laboratory Biom... Metformin Hydro... Pharmacological... Ritonavir Quality-of-Life Questionnaire | 18 Years - | City of Hope Medical Center | |
| Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma | NCT00450814 | Recurrent Plasm... Refractory Plas... | Cyclophosphamid... Laboratory Biom... Oncolytic Measl... Pharmacological... | 18 Years - | Mayo Clinic | |
| Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma | NCT00450814 | Recurrent Plasm... Refractory Plas... | Cyclophosphamid... Laboratory Biom... Oncolytic Measl... Pharmacological... | 18 Years - | Mayo Clinic | |
| Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant | NCT03328936 | Hematopoietic C... Recurrent Plasm... Refractory Plas... | Laboratory Biom... Melphalan Hydro... Melphalan Hydro... Pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma | NCT02506959 | Plasma Cell Leu... Plasmacytoma Recurrent Plasm... Refractory Plas... | Autologous Hema... Busulfan Gemcitabine Hyd... Laboratory Biom... Melphalan Panobinostat Peripheral Bloo... Pharmacological... | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma | NCT03829020 | Recurrent Plasm... Refractory Plas... | Bortezomib Metformin Hydro... Nelfinavir Mesy... | 18 Years - | Mayo Clinic | |
| Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma | NCT00793572 | Refractory Plas... | Autologous Hema... Bortezomib Cyclosporine Cyclosporine Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Nonmyeloablativ... Peripheral Bloo... Syngeneic Bone ... Total-Body Irra... | 18 Years - | Fred Hutchinson Cancer Center | |
| Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) | NCT04439214 | Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Plas... | Nivolumab | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
